Structure Therapeutics
(NASDAQ) GPCR
Structure Therapeutics Financials at a Glance
Market Cap
$2.80B
Revenue (TTM)
$0.00
Net Income (TTM)
-$170.56M
EPS (TTM)
-$2.69
P/E Ratio
-14.61
Dividend
$0.00
Beta (Volatility)
1.07 (Average)
Dividend
$0.00
Beta (Volatility)
1.07 (Average)
Price
$39.52
Volume
507,097
Open
$41.18
Price
$39.52
Volume
507,097
Open
$41.18
Previous Close
$39.34
Daily Range
$39.06 - $41.18
52-Week Range
$15.80 - $94.90
Dividend
$0.00
Beta (Volatility)
1.07 (Average)
Price
$39.52
Volume
507,097
Open
$41.18
Previous Close
$39.34
Daily Range
$39.06 - $41.18
52-Week Range
$15.80 - $94.90
GPCR News
GPCR: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Structure Therapeutics
Industry
Pharmaceuticals
Sector
Health CareEmployees
233
CEO
Raymond C. Stevens, PhD
Website
www.structuretx.comHeadquarters
South San Francisco, CA 94080, US
GPCR Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-15%
Return on Capital
-14%
Return on Assets
-11%
Earnings Yield
-6.84%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$2.80B
Shares Outstanding
71.07M
Volume
507.10K
Avg. Volume
902.59K
Financials (TTM)
Gross Profit
-$3.90M
Operating Income
-$287.57M
EBITDA
-$136.79M
Operating Cash Flow
-$222.20M
Capital Expenditure
-$3.61M
Free Cash Flow
-$225.81M
Cash & ST Invst.
$1.45B
Total Debt
$6.49M
Structure Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
-$1.22M
N/A
Gross Margin
0.00%
N/A
Market Cap
$2.80B
N/A
Market Cap/Employee
$17.15M
N/A
Employees
163
N/A
Net Income
-$76.19M
-62.7%
EBITDA
-$88.43M
-57.8%
Quarterly Fundamentals
Net Cash
$1.45B
+75.2%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$3.18M
-37.8%
Short Term Debt
$2.61M
+5.6%
Return on Assets
-11.31%
N/A
Return on Invested Capital
-14.46%
N/A
Free Cash Flow
$14.09M
+126.8%
Operating Cash Flow
$15.28M
+129.3%